Analyst firms · Morgan Stanley · SGHT

Morgan Stanley SGHT price target and rating history

Sight Sciences Inc. (SGHT) · Health Care

Morgan Stanley rates Sight Sciences Inc. (SGHT) Equal-Weight with a $8.40 price target, as of its latest action on Aug 24, 2023. It has published 3 rating actions on SGHT since August 2021, including 1 upgrade and 1 downgrade. Across 3 firms with a SGHT price target in the last 12 months, the median target is $9.

Current rating
Equal-Weight
Price target
$8.40
Median target, all firms
$9
Actions on SGHT
3

Morgan Stanley price target on SGHT

$41$25$8.4020222023202420252026
Morgan Stanley price target on SGHT, each point a stated target, August 2021 to August 2023.

Every Morgan Stanley rating on SGHT

How other firms rate SGHT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightBuy$14Oct 15, 2026
UBSBuy$7Jul 28, 2026
Piper SandlerOverweight$9Jan 5, 2026

Questions about Morgan Stanley and SGHT

What is Morgan Stanley's price target for SGHT?
Morgan Stanley's latest stated price target for Sight Sciences Inc. (SGHT) is $8.40, from its action on Aug 24, 2023.
What is Morgan Stanley's rating on SGHT?
Morgan Stanley rates SGHT Equal-Weight, a neutral rating, as of Aug 24, 2023.
When did Morgan Stanley last change its view on SGHT?
On Aug 24, 2023, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $12 to $8.40.
How does Morgan Stanley's SGHT target compare with other analysts?
Across 3 firms with a SGHT price target in the last 12 months, the median target is $9.

More SGHT rating histories

All Morgan Stanley ratingsSGHT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.